Collection Bio 2026.07.20

Understanding Different Types of Domestic Bio Companies Through Representative Firms

Comparing different business models like Samsung Biologics, Celltrion, SK Bioscience, Hanmi Pharmaceutical, and Yuhan Corporation

#Bio #CDMO #Domestic Companies #Pharmaceutical and Biotech #Biosimilars

While domestic bio companies are often grouped under one term, their actual business models vary significantly. Some companies focus on contract manufacturing, others develop and sell biosimilars, while some grow based on vaccines, new drugs, anticancer drugs, platform technologies, and traditional pharmaceutical sales. Even the same bio news can be easily misunderstood without knowing the company's business model, which affects revenue structure and risks. This list summarizes representative companies that are helpful to understand domestic pharmaceutical and bio companies by type.

Samsung Biologics

Samsung Biologics is better understood as a CDMO company that produces biopharmaceuticals developed by global pharmaceutical companies, rather than a pharmaceutical company that sells new drugs directly. Its key competitive strengths are large-scale production facilities, quality management capabilities, and securing global clients. When looking at performance, the factory utilization rate, new contracts, production capacity expansion, and entry into new modalities are important.

기업 유형 바이오 CDMO

바로가기

Celltrion

Celltrion is a representative company that has popularized the domestic bio industry through biosimilars. After the patent expiration of original biopharmaceuticals, it develops products that demonstrate similar effects and quality, competing in the global market. The biosimilar business is not only about licensing and production but also crucially involves overseas sales networks, price competition, and expanding prescriptions. It's important to consider new product launches and changes in the market share of existing products together.

기업 유형 바이오시밀러·바이오의약품

바로가기

SK Bioscience

SK Bioscience is a notable company in the vaccine field. Vaccines are tied to public health, making the outbreak of infectious diseases, government procurement, global partnerships, and production facility certification very important. While the strategic value of vaccine production capacity has increased post-pandemic, it should also be noted that demand may fluctuate with the outbreak situation. It's advisable to distinguish between the pipeline and contract manufacturing agreements.

기업 유형 백신·바이오 생산

바로가기

Hanmi Pharmaceutical

Hanmi Pharmaceutical is a company that has built research and development and technology export experience on a foundation of traditional pharmaceuticals. When reading pharmaceutical news, technology export contracts may appear as major positives, but it's essential to consider the contract amounts, milestones, the success of clinical trials, and the possibility of returns. For R&D-focused companies, the quality of the pipeline, clinical stages, and the partner's development commitment significantly impact corporate value.

기업 유형 연구개발 중심 제약사

바로가기

Yuhan Corporation

Yuhan Corporation should be viewed through the lens of its long-established pharmaceutical sales base and its new drug development achievements. Companies with a stable pharmaceutical sales foundation can absorb some of the risks of research and development failures, and successful pipelines can become long-term growth engines. Looking at a comprehensive pharmaceutical company in terms of prescription drugs, over-the-counter drugs, technology exports, and partnerships provides a clearer view of its business structure.

기업 유형 종합 제약사·신약개발

바로가기

Alteogen

Platform technology companies like Alteogen prioritize the range of technology applications and partnerships over specific finished product sales. Platform technologies have great potential for application across various medicines, but commercialization and royalties may take time to materialize. When evaluating related news, it’s important to check contract structures, applicable products, clinical stages, and the development progress of partners.

기업 유형 바이오 플랫폼 기술

바로가기

When looking at bio companies, it's important to check how they earn money, what pipelines they have, and what stage of development they are in, rather than categorizing them broadly as 'growth stocks' just because they are in bio. Companies focused on production, new drug development, vaccines, and biosimilars have different revenue stability and risk of failure. Understanding the business model before the company name allows for a more composed reading of industry news and earnings reports.

한눈에 보기 6개